Free Trial

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Rating of "Moderate Buy" by Brokerages

NewAmsterdam Pharma logo with Medical background

Key Points

  • Analysts have given NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) an average price target of $41.20, with most recommendations categorized as "Moderate Buy."
  • The company reported a quarterly EPS of ($0.15), significantly beating the consensus estimate of ($0.52), and had revenues of $19.15 million for the quarter.
  • Insider activity shows that Director James N. Topper bought 2,520 shares at an average price of $18.43 per share, while COO Douglas F. Kling sold 51,043 shares at an average price of $21.10 per share.
  • Need better tools to track NewAmsterdam Pharma? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $41.20.

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a "neutral" rating and a $27.00 price target on the stock. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Needham & Company LLC reissued a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Finally, Stifel Nicolaus began coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price on the stock.

View Our Latest Analysis on NewAmsterdam Pharma

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.06 during trading hours on Friday, reaching $24.43. 96,833 shares of the company were exchanged, compared to its average volume of 875,237. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -15.08 and a beta of -0.02. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The stock has a 50 day simple moving average of $20.84 and a 200 day simple moving average of $19.98.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. On average, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Douglas F. Kling sold 51,043 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the completion of the sale, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $928,400. This trade represents a 53.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James N. Topper purchased 2,520 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were purchased at an average cost of $18.43 per share, with a total value of $46,443.60. Following the completion of the acquisition, the director owned 3,024,873 shares in the company, valued at approximately $55,748,409.39. This represents a 0.08% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 12,364 shares of company stock valued at $236,839 and have sold 198,612 shares valued at $4,025,887. 20.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares in the last quarter. Quarry LP acquired a new position in NewAmsterdam Pharma during the 1st quarter worth $25,000. Avanza Fonder AB grew its holdings in NewAmsterdam Pharma by 21.0% during the 2nd quarter. Avanza Fonder AB now owns 7,505 shares of the company's stock worth $136,000 after acquiring an additional 1,300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $50,000. Finally, National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $51,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Featured Articles

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Should You Invest $1,000 in NewAmsterdam Pharma Right Now?

Before you consider NewAmsterdam Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.

While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines